# Phase 2 Squamous Cell Carcinoma of: 165 recruiting (2026)

ClinicalTrials.gov lists 165 trials in phase 2 for Squamous Cell Carcinoma of Head and Neck that are recruiting or not yet recruiting.

## The full list

Recruiting Phase 2 Squamous Cell Carcinoma of Head and Neck trials: 165 rows for $8.25, recruiting or not yet recruiting on ClinicalTrials.gov. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 7 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/squamous-cell-carcinoma-of-head-and-neck

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 165
- Recruiting or not yet: 165
- Read on: November 19, 2026

## Trials

The 25 newest of 165, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 9, 2026 | NCT07923877 | Induction Chemoimmunotherapy to Prevent Laryngectomy in Advanced Laryngeal Cancer and Hypopharyngeal Cancer | Mayo Clinic | Phase 2 | Not yet recruiting | Advanced Laryngeal Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Stage III Laryngeal Cancer AJCC v8... | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07923877) |
| November 5, 2026 | NCT07919444 | Effectiveness of Phenotype-based Pain Management Guidelines for Head and Neck Cancer Related Pain: a Pilot Study | Shaukat Khanum Memorial Cancer Hospital & Research Centre | Phase 2 | Recruiting | Cancer Pain, Orofacial Pain, Head and Neck Cancer, Head and Neck (HNSCC) | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07919444) |
| November 4, 2026 | NCT07915258 | Becotatug Vedotin Plus Pucotenlimab in Locally Advanced Head and Neck Squamous Cell Carcinoma With Suboptimal Response to Induction... | Sun Yat-sen University | Phase 2 | Not yet recruiting | Squamous Cell Carcinoma of Head and Neck (SCCHN) | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07915258) |
| October 30, 2026 | NCT07906587 | Locally Advanced Resectable Head and Neck Squamous Cell Carcinoma: A Prospective, Single-Arm Clinical Study | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 | Recruiting | Head and Neck Squamous Cell Carcinoma | 86 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07906587) |
| October 28, 2026 | NCT07901803 | Aspirin and PAClitaxel in Head & Neck Squamous Cell Carcinoma | Washington University School of Medicine | Phase 2 | Not yet recruiting | Head and Neck (HNSCC), Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Head and Neck... | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07901803) |
| October 22, 2026 | NCT07888816 | Optimizing Response to Immunotherapy With Online Adaptive Pulsed Radiotherapy in Incurable Head and Neck Cancers | University Health Network, Toronto | Phase 2 | Not yet recruiting | Head and Neck Squamous Cell Carcinoma (HNSCC) | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07888816) |
| September 28, 2026 | NCT07844551 | ImmunoADC Therapy for Induction Conversion in Patients With Stage IVB OSCC/OPSCC | Huashan Hospital | Phase 2 | Not yet recruiting | Stage IVB Oral Cavity Squamous Cell Carcinoma, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8 | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07844551) |
| September 25, 2026 | NCT07840456 | Safety and Efficacy of Ruxolitinib in Patients With HNSCC and High NLR Treated With Pembrolizumab - The Phase 2 InflammaSTOP Trial | University Hospital, Basel, Switzerland | Phase 2 | Not yet recruiting | Carcinoma, Squamous Cell of Head and Neck HNSCC | 66 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07840456) |
| September 17, 2026 | NCT07825597 | Indocyanine Green With Near Infrared Imaging for Intraoperative Visualization of Head and Neck Squamous Cell Carcinoma | Washington University School of Medicine | Phase 2 | Recruiting | Head and Neck Squamous Cell Carcinoma | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07825597) |
| September 10, 2026 | NCT07814287 | Becotatug Vedotin Plus Pucotenlimab and Platinum Chemotherapy in Locally Advanced Epidermal Growth Factor Receptor (EGFR)-Positive Head and... | Sponsor not shown (see the record) | Phase 2 | Recruiting | Head and Neck Squamous Cell Carcinoma, HNSCC | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07814287) |
| September 10, 2026 | NCT07812467 | Rimegepant-Sensitized Neoadjuvant Chemoimmunotherapy for Oral or Oropharyngeal Squamous Cell Carcinoma | Shanghai Zhongshan Hospital | Phase 2 | Not yet recruiting | Oral Squamous Cell Carcinoma (OSCC), Oropharyngeal Squamous Cell Carcinoma (OPSCC) | 220 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07812467) |
| September 8, 2026 | NCT07807163 | A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCC | Bicara Therapeutics | Phase 2 | Recruiting | Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07807163) |
| August 31, 2026 | NCT07796126 | Sequential Toripalimab and Paclitaxel in Patients With Head and Neck Squamous Cell Cancer (HNSCC) and Poor Performance Status | Barbara Ann Karmanos Cancer Institute | Phase 2 | Not yet recruiting | Squamous Cell Carcinoma Head and Neck Cancer (HNSCC) | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07796126) |
| August 27, 2026 | NCT07788950 | A Study of BL-M08D1 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 2 | Not yet recruiting | Head and Neck Squamous Cell Carcinomas, Solid Tumors | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07788950) |
| August 25, 2026 | NCT07783581 | Proton Spatially Fractionated Radiotherapy or Photon Stereotactic Body Radiotherapy in Combination With Pembrolizumab Before Surgery for... | Mayo Clinic | Phase 2 | Recruiting | Locally Advanced Oral Cavity Squamous Cell Carcinoma, Locally Recurrent Oral Cavity Squamous Cell Carcinoma, Oral... | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07783581) |
| August 24, 2026 | NCT07780877 | Response-adapted Postoperative Radiotherapy In Locally Advanced Head and Neck Cancer | Fudan University | Phase 2 | Not yet recruiting | Head & Neck Squamous Cell Carcinoma, Locally Advanced Head and Neck Squamous Cell Carcinoma | 85 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07780877) |
| August 21, 2026 | NCT07778732 | Adebrelimab Combined With Dalpiciclib Isethionate Plus Chemotherapy for Neoadjuvant Treatment of Locally Advanced Head and Neck Squamous... | Tianjin Medical University Cancer Institute and Hospital | Phase 2 | Not yet recruiting | HNSCC | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07778732) |
| August 21, 2026 | NCT07778368 | A Multicenter, Prospective, Phase II Study of TROP-2 ADC in Combination With Toripalimab for Resectable Locally Advanced Oral Squamous Cell... | Shanghai East Hospital | Phase 2 | Not yet recruiting | Oral Squamous Cell Carcinoma (OSCC) | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07778368) |
| August 20, 2026 | NCT07776340 | Induction PD-1 Inhibitor and Chemotherapy Followed by Chemoradiotherapy in Unresectable or Inoperable HPV-negative LA-HNSCC | Fudan University | Phase 2 | Not yet recruiting | HPV-unrelated Head and Neck Squamous Cell Carcinoma | 104 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07776340) |
| August 17, 2026 | NCT07766889 | Neoadjuvant Presurgical Becotatug Vedotin (MRG003) Plus Pucotenlimab (HX008) in Oral Cavity Squamous Cell Carcinoma | Sun Yat-sen University | Phase 2 | Not yet recruiting | Oral Squamous Cell Carcinoma, Head and Neck Cancer, Locally Advanced Head and Neck Cancer, Neoadjuvant Therapy | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07766889) |
| August 7, 2026 | NCT07751289 | Anti-PD-1 Therapy in Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Recurrent Head and Neck Squamous Cell Carcinoma | 217 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07751289) |
| August 7, 2026 | NCT07751276 | Perioperative Finotonlimab Plus Chemotherapy in Untreated Stage II HNSCC | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Head and Neck Squamous Cell Carcinoma HNSCC | 142 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07751276) |
| August 4, 2026 | NCT07744126 | A Study to Assess Adverse Events, Change in Disease Activity and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan With IV... | AbbVie | Phase 2 | Recruiting | Head and Neck Squamous Cell Carcinoma | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07744126) |
| July 6, 2026 | NCT07683507 | Becotatug Vedotin Plus PD-1 Inhibitor for Head and Neck Squamous Cell Carcinoma | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Head and Neck Squamous Cell Carcinoma | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07683507) |
| July 1, 2026 | NCT07679997 | Trilaciclib Combined With Immunochemotherapy for R/M HNSCC | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 2 | Not yet recruiting | Head & Neck Squamous Cell Carcinoma | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07679997) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 11 |
| Sun Yat-sen University | 6 |
| National Cancer Institute (NCI) | 5 |
| Washington University School of Medicine | 4 |
| Shanghai Zhongshan Hospital | 4 |
| Fudan University | 4 |
| West China Hospital | 3 |
| Dana-Farber Cancer Institute | 3 |
| Memorial Sloan Kettering Cancer Center | 3 |
| Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | 3 |
| Zhejiang Provincial People's Hospital | 3 |
| Gruppo Oncologico del Nord-Ovest | 3 |
| Mayo Clinic | 3 |
| [Sichuan Baili Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/sichuan-baili-pharmaceutical-co-ltd) | 3 |
| University of Maryland, Baltimore | 2 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2 |
| University Health Network, Toronto | 2 |
| London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 2 |
| Tianjin Medical University Cancer Institute and Hospital | 2 |
| University of Michigan Rogel Cancer Center | 2 |
| Medical University of South Carolina | 2 |
| Sir Run Run Shaw Hospital | 2 |
| [CSPC Megalith Biopharmaceutical Co.,Ltd.](https://specstream.ai/data/clinical-trials/company/cspc-megalith-biopharmaceutical-co-ltd) | 2 |
| Beijing Tongren Hospital | 2 |
| NRG Oncology | 1 |

## By country

| Country | Trials |
| --- | --- |
| China | 65 |
| United States | 57 |
| France | 6 |
| Germany | 5 |
| Canada | 5 |
| Italy | 5 |
| Australia | 5 |
| Switzerland | 3 |
| Taiwan | 3 |
| Spain | 3 |
| Japan | 2 |
| India | 2 |
| Netherlands | 1 |
| Singapore | 1 |
| Pakistan | 1 |
| Egypt | 1 |
| Malaysia | 1 |
| Uganda | 1 |
| Brazil | 1 |
| South Korea | 1 |
| United Kingdom | 1 |
| Vietnam | 1 |
| Russia | 1 |
| Sweden | 1 |
| Poland | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Stock brokers in the United States](https://specstream.ai/data/businesses/stock-brokers/united-states)
- [Tableware suppliers in the United States](https://specstream.ai/data/businesses/tableware-suppliers/united-states)
- [Test preparation centers in the United States](https://specstream.ai/data/businesses/test-preparation-centers/united-states)
- [Tower communication companies in the United States](https://specstream.ai/data/businesses/tower-communication-companies/united-states)
- [Truck parts suppliers in the United States](https://specstream.ai/data/businesses/truck-parts-suppliers/united-states)
- [Valet services in the United States](https://specstream.ai/data/businesses/valet-services/united-states)
